Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Observational Study of Dupilumab for Prurigo Nodularis
ChiCTR2500099847Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dupilumab in prurigo nodularis (PN) and atopic dermatitis (AD), sponsored by First Hospital of China Medical University. Primary endpoint: Real-world use pattern of dupilumab for prurigo nodularis. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
03
Conditions
prurigo nodularis (PN)atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2500099847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099847.